Andrew M Bellizzi, MD
Overview
Andrew M Bellizzi, MD, is Professor of Pathology and Cell Biology and Director of Surgical Pathology at Columbia University Irving Medical Center. He is an internationally recognized expert in gastrointestinal surgical pathology, immunohistochemistry, general oncopathology, and neuroendocrine tumor pathology. His academic work focuses on translating advances in molecular genetics and developmental biology into practical immunohistochemical diagnostic tools, an approach he has termed “next-generation immunohistochemistry".
He previously held faculty positions at Brigham and Women’s Hospital and the University of Iowa, where he established the GI Pathology Service Line and GI Pathology Fellowship and led the expansion of the Immunohistochemistry Laboratory.
His national and international leadership roles have included Chair of the College of American Pathologists Immunohistochemistry Committee, senior author of the CAP guideline on immunohistochemical assay validation, Secretary-Treasurer of the International Society for Immunohistochemistry and Molecular Morphology, and Editor-in-Chief of Applied Immunohistochemistry & Molecular Morphology.
Areas of Expertise / Conditions Treated
- Gastrointestinal Pathology
- Immunohistochemistry
- Liver Pathology
- Surgical Pathology
Academic Appointments
- Professor of Pathology and Cell Biology at CUMC
Administrative Titles
- Director of Surgical Pathology
Gender
- Male
Schedule an Appointment
Connect Patient Portal
For existing patients, login to make an appointment, view documentation or contact your care provider.
Credentials & Experience
Education & Training
- MD, Northwestern University Medical School (2004)
- Residency: AP/CP, University of Virginia Health System (2008)
- Fellowship: GI/Liver Pathology Fellowship, The Ohio State University Hospital (2009)
Board Certifications
- Anatomic and Clinical Pathology
Honors & Awards
- Iowa City VA Medical Center Pathology and Lab Teaching Award (2024)
- University of Iowa Carver College of Medicine GME Excellence in Clinical Coaching Award (2023)
- University of Iowa Department of Pathology Resident Teaching Award (2022)
- College of American Pathologists (CAP) Laboratory Improvement Programs Service Award (2022)
- Alpha Omega Alpha (2003)
Research
Dr. Bellizzi’s scholarship includes diagnostic biomarker discovery and the development of practical diagnostic frameworks for tumors of uncertain lineage, carcinoma of unknown primary, and neuroendocrine neoplasia. He has also played a leading role in practice guideline development in gastrointestinal and neuroendocrine cancers and in the standardization, validation, and quality assurance of immunohistochemistry laboratory practices.
Selected Publications
- Grewal US, Gosse M, Concors SJ, Gonzalez RS, Ear PH, Halperin DM, Chandrasekharan C, Singh S, Bellizzi AM. Grade Progression and High-Grade Transformation in Neuroendocrine Neoplasms. Endocr Relat Cancer. 2026 Jul 13:ERC-26-0017.
- Singh PN, Hadj Bachir E, Howe JR, Bellizzi AM, Cejas P, Madha-Krause S, Epstein CB, Chan JA, Bernstein B, Kulke MH, Zhou Q, Shivdasani RA. Multiomic analyses delineate human neuroendocrine tumor cell states in relation to normal enteroendocrine cell ontogeny. J Clin Invest. 2026 May 21;136(13):e197772.
- Ear PH, Hueser SA, Townsend RE, Maxwell JE, Abusada E, Chan CHF, Quelle DE, Dillon JS, Howe JR, Bellizzi AM. Variable GLP-1 receptor expression across diverse neuroendocrine neoplasms: implications for incretin therapies. Endocr Oncol. 2025 Nov 25;5(1):e250051.
- Abukhiran I, Neyaz A, Kop M, Baroudi I, Christensen D, Baki MA, Surakji H, Shaker N, Bedell ML, Jasser J, Rammal R, Deebajah M, Pai R, Pantanowitz L, Bellizzi A. Optimal Approaches to Grading Enteropancreatic Neuroendocrine Tumors Using Ki-67 Proliferation Index: Hotspot and Whole-Slide Digital Quantitative Analysis. Mod Pathol. 2025 Aug;38(8):100780.
- Loree JM, Chan D, Lim J, Stuart H, Fidelman N, Koea J, Posavad J, Cummins M, Doucette S, Myrehaug S, Naraev B, Bailey DL, Bellizzi A, Laidley D, Boyle V, Goodwin R, Del Rivero J, Michael M, Pasieka J, Singh S. Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs. JAMA Oncol. 2024 Dec 1;10(12):1707-1720.
- Chauhan A, Chan K, Halfdanarson TR, Bellizzi AM, Rindi G, O'Toole D, Ge PS, Jain D, Dasari A, Anaya DA, Bergsland E, Mittra E, Wei AC, Hope TA, Kendi AT, Thomas SM, Flem S, Brierley J, Asare EA, Washington K, Shi C. Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2024 Jul-Aug;74(4):359-367.
- Goldsmith JD, Troxell ML, Roy-Chowdhuri S, Colasacco CF, Edgerton ME, Fitzgibbons PL, Fulton R, Haas T, Kandalaft PL, Kalicanin T, Lacchetti C, Loykasek P, Thomas NE, Swanson PE, Bellizzi AM. Principles of Analytic Validation of Immunohistochemical Assays: Guideline Update. Arch Pathol Lab Med. 2024 Jun 1;148(6):e111-e153.
- Bellizzi AM. p53 as Exemplar Next-Generation Immunohistochemical Marker: A Molecularly Informed, Pattern-Based Approach, Methodological Considerations, and Pan-Cancer Diagnostic Applications. Appl Immunohistochem Mol Morphol. 2023 Aug 1;31(7):507-530.
- Eads JR, Halfdanarson TR, Asmis T, Bellizzi AM, Bergsland EK, Dasari A, El-Haddad G, Frumovitz M, Meyer J, Mittra E, Myrehaug S, Nakakura E, Raj N, Soares HP, Untch B, Vijayvergia N, Chan JA. Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms. Endocr Relat Cancer. 2023 Jul 11;30(8):e220206.
- Fernandez AI, Liu M, Bellizzi A, Brock J, Fadare O, Hanley K, Harigopal M, Jorns JM, Kuba MG, Ly A, Podoll M, Rabe K, Sanders MA, Singh K, Snir OL, Soong TR, Wei S, Wen H, Wong S, Yoon E, Pusztai L, Reisenbichler E, Rimm DL. Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue. JAMA Oncol. 2022 Apr 1;8(4):1-4.
- Salgado R, Bellizzi AM, Rimm D, Bartlett JMS, Nielsen T, Holger M, Laenkholm AV, Quinn C, Cserni G, Cunha IW, Alvarado-Cabrero I, Cree I. How current assay approval policies are leading to unintended imprecision medicine. Lancet Oncol. 2020 Nov;21(11):1399-1401.
- Bellizzi AM. An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin. Adv Anat Pathol. 2020 May;27(3):114-163.
- Baranov E, McBride MJ, Bellizzi AM, Ligon AH, Fletcher CDM, Kadoch C, Hornick JL. A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma. Am J Surg Pathol. 2020 Jul;44(7):922-933.
- Bellizzi AM. Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you? Hum Pathol. 2020 Feb;96:8-33.
- Bellizzi AM. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistry. Adv Anat Pathol. 2013 Sep;20(5):285-314.
- Herrera AF, Soriano G, Bellizzi AM, Hornick JL, Ho VT, Ballen KK, Baden LR, Cutler CS, Antin JH, Soiffer RJ, Marty FM. Cord colitis syndrome in cord-blood stem-cell transplantation. N Engl J Med. 2011 Sep 1;365(9):815-24.
- Wang X, Ouyang H, Yamamoto Y, Kumar PA, Wei TS, Dagher R, Vincent M, Lu X, Bellizzi AM, Ho KY, Crum CP, Xian W, McKeon F. Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell. 2011 Jun 24;145(7):1023-35.